DRD4 and glioblastoma: Having established the role of DRD4 in the tumorigenicity, metastatic and GSC-like phenotypes of GBM, as well as its association with CD133 positivity, we then investigated the probable inhibitory effect and therapeutic efficacy of LCC-09 on the CD133+ TMZ-resistant U87MG or D54MG cells in particular.